561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19

BACKGROUND: Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Here we report safety of RDV in patients with moderate COVID-19. METHODS: We conducted an open-label, phase 3 trial (NCT04252664) in hospitalized patients with confirmed SARS...

Descripción completa

Detalles Bibliográficos
Autores principales: Criner, Gerard J, Ahn, Mi Young, Huhn, Gregory, Subramanian, Aruna, Lumbreras, Carlos, Schmiedel, Stefan, Hyland, Robert H, Suri, Vithika, Cao, Huyen, Wang, Hongyuan, SenGupta, Devi, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Chen, Yao-Shen, Günthard, Huldrych, Sanz-Moreno, D Jose, Aberg, Judith A, Nicastri, Emanuele, Tsang, Owen Tak-Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777368/
http://dx.doi.org/10.1093/ofid/ofaa439.755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777368/
http://dx.doi.org/10.1093/ofid/ofaa439.755

Ejemplares similares